Form 4 for JSPR Jasper Therapeutics, Inc.
Accepted 2023-04-11 00:00:00 ET · period of report 2023-01-27 · accession 0001209191-23-024058 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-04-11 | 2023-01-27 | JSPR | Qiming U.S. Healthcare GP II, LLC | 10% | P - Purchase | $1.50 | +2.67M | 8.52M | +46% | +$4.00M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Voting Common Stock | 2023-01-27 | P | A | 2,666,666 | $1.50 | 8,519,648 | D | — | — | (F1) The securities are directly held by Qiming U.S. Healthcare Fund II, L.P. ("Qiming"). The general partner of Qiming is Qiming U.S. Healthcare GP II, LLC ("Qiming GP"). Gary Rieschel and Mark McDade are the managing partners of Qiming GP and may be deemed to share voting and dispositive power over the shares held by Qiming. Each of Qiming GP and Messrs. Rieschel and McDade disclaims beneficial ownership of such shares except to the extent of its or his pecuniary interest therein. |